CDT Equity vs Kala Bio
CDT and KALA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDT and KALA compare
Kala Bio is the larger company, worth 8.5 times as much as CDT Equity ($2.7M against $315K).
Kala Bio scores higher on the StockData Score (6 against 5 for CDT Equity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDT | KALA |
|---|---|---|
| Size and price | ||
| Market cap | $315K | $2.7M |
| Share price | $0.400 | $0.139 |
| Change, 1 year | −100.0% | −99.6% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | 3.49 | 0.34 |
| Employees | 4 | 6 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.0× (better) | 0.3× |
| Profitability | ||
| Return on equity | −69.7% (better) | −345% |
| Return on invested capital | −53.7% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.13 | 6.88 (better) |
| Altman Z-score | −1.94 (better) | −96.83 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 3.2% |
| Insider net buying, 12 months | −$2.9M | $0 (better) |
Go deeper
- CDT stock overview
- CDT income statement
- CDT valuation and score
- KALA stock overview
- KALA income statement
- KALA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.